Browse STAT5A

Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Translocated into the nucleus in response to phosphorylation.
Domain PF00017 SH2 domain
PF01017 STAT protein
PF02864 STAT protein
PF02865 STAT protein
Function

Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Mediates cellular responses to ERBB4. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the GAS element and activates PRL-induced transcription. Regulates the expression of milk proteins during lactation.

> Gene Ontology
 
Biological Process GO:0000255 allantoin metabolic process
GO:0001667 ameboidal-type cell migration
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0006101 citrate metabolic process
GO:0006103 2-oxoglutarate metabolic process
GO:0006105 succinate metabolic process
GO:0006107 oxaloacetate metabolic process
GO:0006520 cellular amino acid metabolic process
GO:0006549 isoleucine metabolic process
GO:0006573 valine metabolic process
GO:0006600 creatine metabolic process
GO:0006631 fatty acid metabolic process
GO:0006790 sulfur compound metabolic process
GO:0007259 JAK-STAT cascade
GO:0007589 body fluid secretion
GO:0007595 lactation
GO:0009081 branched-chain amino acid metabolic process
GO:0009755 hormone-mediated signaling pathway
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019530 taurine metabolic process
GO:0030335 positive regulation of cell migration
GO:0030879 mammary gland development
GO:0032941 secretion by tissue
GO:0035264 multicellular organism growth
GO:0038161 prolactin signaling pathway
GO:0040014 regulation of multicellular organism growth
GO:0040017 positive regulation of locomotion
GO:0043434 response to peptide hormone
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0043648 dicarboxylic acid metabolic process
GO:0046449 creatinine metabolic process
GO:0048638 regulation of developmental growth
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050878 regulation of body fluid levels
GO:0051272 positive regulation of cellular component movement
GO:0060396 growth hormone receptor signaling pathway
GO:0060397 JAK-STAT cascade involved in growth hormone signaling pathway
GO:0060416 response to growth hormone
GO:0071375 cellular response to peptide hormone stimulus
GO:0071378 cellular response to growth hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072338 cellular lactam metabolic process
GO:0072350 tricarboxylic acid metabolic process
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097696 STAT cascade
GO:1901605 alpha-amino acid metabolic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:2000147 positive regulation of cell motility
Molecular Function GO:0004713 protein tyrosine kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04917 Prolactin signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1839124: FGFR1 mutant receptor activation
R-HSA-982772: Growth hormone receptor signaling
R-HSA-168256: Immune System
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-1266695: Interleukin-7 signaling
R-HSA-1251985: Nuclear signaling by ERBB4
R-HSA-1170546: Prolactin receptor signaling
R-HSA-162582: Signal Transduction
R-HSA-1236394: Signaling by ERBB4
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5655302: Signaling by FGFR1 in disease
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-1839117: Signaling by cytosolic FGFR1 fusion mutants
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STAT5A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between STAT5A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27465917B-cell LymphomaPromote immunity (NK cell function)IL-15 augmented mammalian target of rapamycin (mTOR) signaling, which correlated with increased expression of genes related to cell metabolism and respiration. Moreover, mTOR-independent STAT-5 signaling contributed to improved NK-cell function during cytokine activation but not following cytokine withdrawal. Finally, expression of IL-15 correlated with cytolytic immune functions in patients with B-cell lymphoma and favorable clinical outcome. These findings highlight the importance of mTOR-regulated metabolic processes for immune cell functions and argue for implementation of IL-15 in adoptive NK-cell cancer therapy.
16169484MelanomaResistant to immunotherapySignificantly, the knockdown of STAT5 in interferon-resistant melanoma cells restored the growth-inhibitory response to IFNalpha. The overexpressed STAT5 diminished IFNalpha-triggered STAT1 activation, most evidently through upregulation of the inhibitor of cytokine-signaling CIS. Our data demonstrate that overexpression and activation of STAT5 enable melanoma cells to overcome cytokine-mediated antiproliferative signaling.
25125657melanomaPromote immunityMechanistically, in CD8(+) T cells, exposure to CCDC134 promoted cell proliferation through the JAK3-STAT5 pathway, a classic feature of many cytokines of the common gamma-chain (gamma(c)) cytokine receptor family.
21796616MelanomaPromote immunityThe production of multiple cytokines (IFNgamma, TNFalpha, IL-2) and upregulation of LAMP-1 (CD107a) by tumor (Melan-A/MART-1) specific T-cells was comparable to virus (EBV-BMLF1) specific CD8 T-cells. Furthermore, phosphorylation of STAT1, STAT5 and ERK1/2, and expression of CD3 zeta chain were similar in tumor- and virus-specific T-cells, demonstrating functional signaling pathways.
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STAT5A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STAT5A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3220.261
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2910.885
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3460.813
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0250.947
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5150.817
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7090.807
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0220.953
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1790.914
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3710.854
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0060.476
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1250.591
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0360.699
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STAT5A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STAT5A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STAT5A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STAT5A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STAT5A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STAT5A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STAT5A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTAT5A
Namesignal transducer and activator of transcription 5A
Aliases
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STAT5A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.